A Novel RXR Agonist, UAB30, Inhibits Rhabdomyosarcoma Cells in Vitro

BACKGROUND: While patients with early stage rhabdomyosarcoma (RMS) have seen steady improvement in prognosis over the last fifty years, those with advanced stage or high grade disease continue to have a dismal prognosis. Retinoids have been shown to cause growth suppression and terminal differentiat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Surg Res
Main Authors: Williams, Adele P., Waters, Alicia M., Stewart, Jerry E., Atigadda, Venkatram R., Mroczek-Musulman, Elizabeth, Muccio, Donald D., Grubbs, Clinton J., Beierle, Elizabeth A.
Formato: Artigo
Idioma:Inglês
Publicado: 2018
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6007849/
https://ncbi.nlm.nih.gov/pubmed/29907230
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jss.2018.02.057
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares